Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have you done any DD on the CEO Dr. Michael Korenko? If not and you're looking for a bit more confidents in the company then do a little digging on the Doc. He was hand picked by a group of investors and top brass. Doc been a perfect fit and Savior for Vivos inc for the past 6 years by pulling us out of a massive financial mess. I never met Dr. Korenko but my confidence level for him and company is pegged at max.
RDGL
Then slap the ask.
RDGL
Easy to be frustrated when we know what we’re potentially sitting on!
All good!
I understand defending the company, it wasn’t my intention to bash it, just thought there was an opportunity to better serve investors and shareholders with confirmations that things are still on track and that it might be worth asking for. I do it with my business all the time - just a quick follow up note with any timeline adjustments or what’s been completed thus far. That’s all. I got a bit snarky too and I also apologize - let’s just all be happy they already thought the same way and hopefully gives investors the confidence to keep propelling our PPS upwards :)
I now own 328,000 shares at $0.1038 cost average. Can't wait for the IDE submission!!
First trading day of June— next Monday the 3rd. Weekly updates around the corner. RDGL$$$.
Or perhaps dilution selling is over? I have an order in for 21k shares at 16 cents.
I may have complained a lot over the last couple of years, but that was just frustration at what I perceived to be a poor lack of focus on IDE. I have NEVER doubted the science, and with IDE submittal coming in the next 5 weeks, I'm adding as much as I can below 18 cents.
And CSTI ruining it as usual
Looks like the weekend posting helped trigger some nice share price action!
Same here … let’s go $RDGL
Agreed and doing my part , great company with a great future.
$RDGL
Well said and agreed!
Everyone on this board needs to due their part to drive exposure towards RDGL. Make a post on Reddit / FB / LinkedIn / X TODAY. I guarantee you any investor that has any talent for evaluating promising investments will be interested. All longs here need to be a force multiplier for Vivos’s marketing arm… it will benefit all of us. Now go out there and spread the word!!!
Well....that was "soon"!!
Solid buying this morning as expected
Fairly quiet this morning but I imagine things will pick up rather soon.
That is the link - thank you for sharing! I signed up as well.
OK, I was wrong...I am finding myself very excited that they have committed (via email to only those who signed up for direct contact through their website) to submitting the IDE before end of month and we will be getting weekly updates.
Sorry DiamondNebula31, I apparently decided to respond to posts like a bit of an ass yesterday.
Thank you wrinklesobw, that is very good to know!
I am assuming it is this link?
https://radiogel.com/join-our-newsletter
It notes they will send you PRs directly, but it sounds like you also get less informal email updates too?
Awesome, signed up
Excellent post!!!
If you haven’t already, I suggest getting on the. Company website and select getting updates directly from the company by email, these updates are supposed to get to you before they announce them.
They put one out yesterday, saying that the IDE will be submitted before the end of June and that they will start putting weekly updates on their website.
When you do this check your spam folder that’s where mine was.
Quiet morning so far. Would love to see submission this week
Patience for outpatient cancer patients coming soon imo brought to you by RDGL DR KORENKO AND MAYO CLINIC
Twitter!
Well, let’s hope there are meaningful things to say as we get close. I’m loving the timing after the last few days on here 🤙🏻
I love the visual in the blog of 6 images of a tumor being disintegrated by radiogel until its obliterated! That is the visual I, as someone not yet killed by cancer, would love to see on a tee-shirt!
Who/where does it say it is a weekly blog? They have long had a blog. I missed it if there was anywhere it said it was going to be weekly. Frankly that would not excite me because if someone decides to talk once a week whether they have anything meaningful to say or not they are going to start talking crap quick.
Heading into beast mode tomorrow!
A weekly blog! This is more like it 🙌🏻 great to see
Blog post:
"IDE Update - The team at RadioGel™ is reviewing the final draft for IDE Submission. According to the FDA Investigational Device Exemption process, upon receipt of an IDE application, sponsors are notified via email of the date that FDA received the original application and the IDE number assigned. An IDE application is considered approved 30 days after it has been received by the FDA, unless the FDA otherwise informs the sponsor via email prior to 30 calendar days from the date of receipt, that the IDE is approved, approved with conditions, or disapproved. In cases of disapproval, a sponsor has the opportunity to respond to the deficiencies and/or to request a regulatory hearing under 21 CFR Part 16. Vivos Inc who holds the international trademark for RadioGel™ will be submitting the IDE before the end of June 2024."
Me too. Got laid off a few years ago and had to burn through some retirement funds. I am riding this one to full FDA approval or BO. Whichever comes first. Not a whale like some here claim to be. I have 340K. Enough to let me retire if the right price hits.
Don’t take a few people’s response as the Whole Board. As humans we all tend to generalize but, board is way more than just a few folks. Which should also be OK. Free speech
I am absolutely a stockholder, like I mentioned before I’m sitting on 500k. I bought a large quantity last year in the .06 days, and then loaded up again when we went from .13 back down to .07 briefly.
If my so much as mentioning that media management is doing anything but shitting rainbows triggers this response in all of you, like I said I regret joining the board. I’ll leave you to your pumping 💪🏻
I will take that as well. Won’t complain a bit. Obviously it’s a very very very slim chance of such things happening. I posted that just to be posting. If by any chance this goes to $8 or above, I could literally retire financially.
No way. BO for much higher. Need at least $8 if not &12 - $13
Diamond in the rough ....
the pa thinks they are important lol
other meanings of pa equals ???
7
The idiot apologizing to an idiot lol now who's the idiot 🤣
This is not a grammar board
This is not a spelling class
This is a stock board....maybe you forgot. Your method of engagement in my opinion is intentional to try and hurt us all which is manipulation. Presumably you are not a stockholder.
Most of us do not appreciate the style of your deception.
You know this company is heading to success it will soon be more than an otc company.
Sorry someone held your hand on your path towards pa......but maybe you should use your pa for pa work...
or read what myself and others have posted here over the years.
Personally I'm an investor since ADMD. Left when the fudsters were in control of company. Came back when
CEO DR KORENKO took over and what a mess he had to clean up. It's the current
CEO DR KORENKO taking this company to human clinical trials with Mayo clinic in control.
So if you are a real PA you surely can add the math.
7
But but but I’m an investor and I deserve daily updates.
No wait i demand daily updates.
Welcome to the OTC bitches be happy with what you get.
Please in detail explain to me how they can expand and push on vivos when vivos has not been approved for human use as of yet.
Please explain in detail how they push the process for vivos, when all testing is outsourced.
Please in detail how a start up company in the OTC is going to be more involved in pushing the testing and review process.
Please in details how this company can do that.
There’s no pushing vivos, the big pharma don’t want it, they love chemo it’s their bread winner.
So please for the love of god in detail what can they do.
Push the FDA, that would be an absolutely horrendous idea, as a company you don’t push the FDA.
Again you keep saying that they need to be pushing the ide.
How in the fuck can they do that.
Again all the testing is outsourced, pearl is a 3rd party company doing the review of the vx2 study that was requested by the FDA.
So again in detail please explain how the company can push these test results and the review by a 3rd party.
You have been bitching about this for years so now I’m calling your ass out.
In detail how do you fast track all this.
To All,
This will be my last post here, before we all make a boatload of money. Forgive me as it’s a long one. Been in since 2020. I’ve recently overweighted up to 40% into RDGL because the next SP catalyst is basically a sure thing. (I believe in the company but it won’t be sitting in my 401k for years lol)
With that I have a message to all our regulars:
A) A good leader of a company, never over promises and under delivers and the long haul folk know far too well how many times that’s happened in the past. Seems the team has learned their lesson, so a fairly frequent informal update (all the recent tweets) plus a firm time frame of submission (by end of Q2) without any silly intermediary updates that could get blown is just fine for us.
B) Technical analysis on this stock shows that a run up to 0.20 from 0.05, not too long ago, and a pull back plus consolidation around 0.15, is so healthy it’s not even funny. It’s a spring coiling for release. Pack your bags! Even if you bought right now, a trip back to 20 is money, right?
C) I never realized how serious these forum boys are. Our old friends left and they rotated in a new player with a new style and a new pain point to throw FUD around and everyone is getting gaslit and provoked. They come in neutral and ask a benign question and then start with the critiques that would sound reasonable to anyone new but are so apparently false to anyone that’s been here, even since Jan. Here’s the best bet. When FUDsters are found out, maybe just post and don’t reply. That way the Jackbutt isn’t referenced and highlighted over and over and over again. Lol they will respond no matter what anyway.
D) You can bet that those who bought the Reg-A are receiving comprehensive updates that are way better than a tweet. The fact that it was sold means that progress is being made. Unless you have run your own company, and actually raised capital and been beholden to shareholders whims, you have know idea how hard Dr. k and the team are working behind the scenes just to appease them.
E) I say “them” because I do not include us in the “need to appease batch.” Our collective “panty in wad” nature makes no noise whatsoever. We get the summarized version of what direct investors get in hour+ long convos.
F) Can you imagine the insane amounts of moving parts required to get all of this over the finish line? And yet there are those who sit and ask why the team isn’t spending all their time writing tweets and paying for PRs. What would you like your hard earned investment dollars to go to (I don’t have a dog in the isopet isn’t with it discussion so don’t even try it, I could care less). For me isopet is a dress rehearsal for the product, branding, vendor training and hospital onboarding. All of which can be ported over to radiogel
G) To all who know what the real deal is and only read this forum to make sure we don’t miss any big news, set your take profit order and don’t come back until June 20th lol.
GTLA - LFG - FTF (dm for what the last one means lol)
Chumly I simply refuse to believe you are that devoid of the comprehensive skills required to understand something that has been explained to a degree a small child could understand.
So I'll just assume you enjoy the samll attention you derive from stating the same rather ignorant stuff over and over about isopet
I believe it was stated by catfish that this financing had been in the works prior to the stock ascension. I also believe he stated why it was necessary for it to be done when it was done even though they still had substantial cash on hand .
Human trial s
They are being very transparent on date of submission and they even set a deadline for it end of June. They aren't going to give us a weekly update to narrow that down anymore. Why should they? It doesn't do them any good and they don't anyone a specific date. You should be grateful they put a timeline on the submission. They could just be saying 'soon'. I bet if they told us in two weeks you would be asking why don't they refine that estimate every day.
Not to mention they continue to update us on the progress being made that will allow them to submit (that wrinklesobow listed for you).
Why do you need more frequent updates? Are you going to buy more if its soon? If your smart you will buy more while no one expects it to be very soon...otherwise you will pay more? Are you going to sell? You better off waiting until after submission to sell no matter whether it is 10 days or 30. Are you just wanting someone to hold your hand and tell you everything is going to be all right and you won't lose all your money? Your a grown up that invested in the OTC, man up!
I’m not surprised, just a little annoyed that the only time they repeat their “we are on track” narrative is before they dilute. Even if it’s repetitive, updates always help our side of the coin.
I disagree that engaging us with review updates would do anything but push the stock up. You can’t argue that the lack of engagement with the company is a major deterrent for a lot of investors and hurts us all.
I understand they’re improving, I’m just impatient 😂 and I posted on an ihub board because presumably you’re all also stockholders and presumably you’d all appreciate more information, and perhaps there was an update venue that I wasn’t aware of - or someone might suggest multiple investors submitting a request for more information.
I appreciate the less confrontational and derogatory response, enjoy your evening.
“Public (A)ccountant (always capitalize a designation) explains your lack of understanding (of) (you’re missing a word) how the rest of the world works.
That (no need for the ‘s, and what ‘that’ is referring to, is a bit unclear) equals idiot”.
You know, you’re right. You’re clearly way more educated and thoughtful than I am. I don’t know why I didn’t see it sooner. I apologize.
Ok let’s change the topic a little bit. How about a BO announcement next week for $1.95 per share.
Thank
You
Very
Much
It’s my birthday tomorrow and this would make an incredible gift.
Followers
|
807
|
Posters
|
|
Posts (Today)
|
24
|
Posts (Total)
|
174455
|
Created
|
09/19/06
|
Type
|
Free
|
Moderators nathanial lovethatgreen konshe Three2001 chereb19 Cameron12221 |
The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
What is the market for RadioGel™?
Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.
What is Brachytherapy?
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.
Are there other markets for RadioGel™?
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.
The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
What are the steps for FDA clearance?
Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.
August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018, Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Press Releases 2017 ( Change in Management & Directors Dec 2016)
Dec 20, 2016, AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017, AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017, AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017, AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017, AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017, Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017, AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017, ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017, ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017, Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017, Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™
Independent Analyst Research and Price Target
Presentation(s) from CEO & President, Dr. Mike Korenko.
2017 - LINK HERE
STOCK SYMBOL: OTC: RDGL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |